These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8371916)

  • 1. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens.
    Nagasubramanian S; Sheth GP; Hitchings RA; Stjernschantz J
    Ophthalmology; 1993 Sep; 100(9):1305-11. PubMed ID: 8371916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study.
    Alm A; Villumsen J; Törnquist P; Mandahl A; Airaksinen J; Tuulonen A; Marsk A; Resul B; Stjernschantz J
    Ophthalmology; 1993 Sep; 100(9):1312-6; discussion 1316-7. PubMed ID: 8371917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure.
    Friström B; Nilsson SE
    Arch Ophthalmol; 1993 May; 111(5):662-5. PubMed ID: 8489450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
    Mishima HK; Masuda K; Kitazawa Y; Azuma I; Araie M
    Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes.
    Ziai N; Dolan JW; Kacere RD; Brubaker RF
    Arch Ophthalmol; 1993 Oct; 111(10):1351-8. PubMed ID: 8216015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.
    Watson P; Stjernschantz J
    Ophthalmology; 1996 Jan; 103(1):126-37. PubMed ID: 8628543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.
    Toris CB; Camras CB; Yablonski ME
    Ophthalmology; 1993 Sep; 100(9):1297-304. PubMed ID: 8371915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma.
    Hotehama Y; Mishima HK; Kitazawa Y; Masuda K
    Jpn J Ophthalmol; 1993; 37(3):270-4. PubMed ID: 8295364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma.
    Rulo AH; Greve EL; Geijssen HC; Hoyng PF
    Ophthalmology; 1996 Aug; 103(8):1276-82. PubMed ID: 8764799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure.
    Rulo AH; Greve EL; Hoyng PF
    Ophthalmology; 1997 Sep; 104(9):1503-7. PubMed ID: 9307648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study.
    Rácz P; Ruzsonyi MR; Nagy ZT; Bito LZ
    Arch Ophthalmol; 1993 May; 111(5):657-61. PubMed ID: 8489449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.
    Camras CB
    Ophthalmology; 1996 Jan; 103(1):138-47. PubMed ID: 8628544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.
    Alm A; Stjernschantz J
    Ophthalmology; 1995 Dec; 102(12):1743-52. PubMed ID: 9098273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure.
    Lusky M; Ticho U; Glovinsky J; Weinberger D; Nesher R; Yassur Y; Melamed S
    Ophthalmology; 1997 Oct; 104(10):1720-4. PubMed ID: 9331215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension.
    Susanna R; Giampani J; Borges AS; Vessani RM; Jordao ML
    Ophthalmology; 2001 Feb; 108(2):259-63. PubMed ID: 11158796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
    Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM
    Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2 alpha-isopropyl ester analogues for glaucoma treatment.
    Hotehama Y; Mishima HK
    Jpn J Ophthalmol; 1993; 37(3):259-69. PubMed ID: 8295363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
    Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT
    Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue.
    Diestelhorst M; Krieglstein GK; Lusky M; Nagasubramanian S
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S77-81. PubMed ID: 9154280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.